Description: BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company offers the neutrophil gelatinase-associated lipocalin test, a particle-enhanced turbidimetric test that measures NGAL that is used to supplement clinical evaluation and standard tests; monoclonal antibodies for scientific, pharmaceutical, and clinical research use; enzyme-linked immunosorbent assay kits; IVD automated assays; and generic rapid assay device platform for the development of lateral flow assays. It sells its products through own sales team, distributors, and OEM partnerships. The company was founded in 2000 and is headquartered in Hellerup, Denmark.
Home Page: bioporto.com
Tuborg Havnevej 15
Hellerup,
2900
Denmark
Phone:
45 45 29 00 00
Officers
| Name | Title |
|---|---|
| Mr. Anthony P. Pare | Chief Exec. Officer |
| Mr. Neil A. Goldman CPA | Exec. VP & CFO |
| Lars Otto Uttenthal | Chief Scientific Officer |
| Ms. Gry Husby Larsen | Gen. Counsel |
| Ms. Jennifer Zonderman | VP of Global Marketing & US Commercialization |
| Dr. Christopher Bird | Chief Medical Officer |
| Mr. Nis Kruse | Exec. VP of Strategic Partnerships and GM of EMEA & APAC |
Exchange: CO
Country: DK : Denmark
Currency: Danish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.2232 |
| Price-to-Sales TTM: | 31.0062 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 31 |